Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Price Expected to Rise, TD Cowen Analyst Says

Key Points

• TD Cowen raised its price target for Supernus Pharmaceuticals from $45.00 to $60.00, suggesting a potential upside of 16.05% from the current stock price, and maintaining a "buy" rating.
• Supernus Pharmaceuticals shares have recently seen mixed ratings from analysts, with one upgrade to "strong-buy" and others downgrading to "hold," resulting in an average rating of "buy" with a consensus price target of $62.67.
• The stock has experienced recent trading activity, with a 2.0% increase on Thursday and substantial insider selling, where executives sold a total of 362,741 shares worth $16.39 million over the last three months.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) had its price target increased by equities researchers at TD Cowen from $45.00 to $60.00 in a report released on Thursday,Benzinga reports. The firm currently has a "buy" rating on the specialty pharmaceutical company's stock. TD Cowen's target price indicates a potential upside of 16.05% from the company's current price.

Several other equities analysts have also recently weighed in on the company. Wall Street Zen cut shares of Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, October 3rd. Piper Sandler upgraded Supernus Pharmaceuticals from a "neutral" rating to an "overweight" rating and upped their price objective for the stock from $40.00 to $65.00 in a research report on Thursday, October 9th. Cantor Fitzgerald boosted their target price on Supernus Pharmaceuticals from $46.00 to $63.00 and gave the stock an "overweight" rating in a research note on Tuesday, September 30th. Weiss Ratings restated a "hold (c)" rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Zacks Research upgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, September 17th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $62.67.

Supernus Pharmaceuticals Trading Up 2.0%

Shares of NASDAQ:SUPN traded up $1.03 during trading on Thursday, reaching $51.70. 334,888 shares of the stock were exchanged, compared to its average volume of 649,543. The stock has a 50-day moving average price of $46.47 and a 200-day moving average price of $37.63. The firm has a market cap of $2.90 billion, a PE ratio of 44.97 and a beta of 0.78. Supernus Pharmaceuticals has a 12 month low of $29.16 and a 12 month high of $53.04.

Insider Activity

In other Supernus Pharmaceuticals news, SVP Frank Mottola sold 5,000 shares of the firm's stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $45.87, for a total value of $229,350.00. Following the completion of the sale, the senior vice president owned 15,496 shares of the company's stock, valued at approximately $710,801.52. This trade represents a 24.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Timothy C. Dec sold 11,780 shares of Supernus Pharmaceuticals stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $44.49, for a total transaction of $524,092.20. Following the completion of the sale, the chief financial officer directly owned 1,246 shares of the company's stock, valued at approximately $55,434.54. The trade was a 90.43% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 362,741 shares of company stock worth $16,390,592 in the last three months. Company insiders own 8.80% of the company's stock.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Rubric Capital Management LP bought a new position in shares of Supernus Pharmaceuticals during the 2nd quarter worth $21,908,000. Armistice Capital LLC increased its stake in shares of Supernus Pharmaceuticals by 7.4% in the first quarter. Armistice Capital LLC now owns 5,196,000 shares of the specialty pharmaceutical company's stock worth $170,169,000 after purchasing an additional 360,000 shares in the last quarter. Sofinnova Investments Inc. raised its position in shares of Supernus Pharmaceuticals by 53.5% in the second quarter. Sofinnova Investments Inc. now owns 799,253 shares of the specialty pharmaceutical company's stock valued at $25,192,000 after purchasing an additional 278,575 shares during the period. GW&K Investment Management LLC boosted its holdings in Supernus Pharmaceuticals by 14.6% in the 1st quarter. GW&K Investment Management LLC now owns 1,382,441 shares of the specialty pharmaceutical company's stock worth $45,275,000 after buying an additional 176,091 shares during the period. Finally, Nuveen LLC purchased a new position in Supernus Pharmaceuticals in the 1st quarter valued at approximately $4,393,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.